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ABSTRACT
Objectives: To determine if low-dose estrogen replace-
ment can be added to GnRH agonist therapy after three
months to reduce hypoestrogenic symptoms while allow-
ing continued relief of pain in patients with endometrio-
sis.
Materials and Methods: Thirteen women with
endometriosis and pain were treated with six months of
leuprolide acetate in a prospective, randomized double-
blind placebo controlled study.  After three months of
therapy, six subjects initiated oral estradiol 1 mg daily,
and seven received an identical placebo.  
Results: Dysmenorrhea improved in both groups, and
dyspareunia significantly improved in the GnRH agonist
plus placebo group.  The mean pain scores of the oral
estrogen group tended to be higher than the placebo
group, and hot flushes tended to be less severe with
estrogen treatment.  However, differences observed
between the study and placebo groups did not reach sta-
tistical significance.
Conclusion: In a prospective, randomized study, low-
dose estrogen replacement increases endometriosis-relat-
ed pain during GnRH agonist therapy.  The study was
terminated after the first 13 subjects due to the concern-
ing trend toward recurrent symptoms in women who
received oral estradiol during GnRH agonist therapy for
endometriosis-related pain.  With the trend toward
increasing pain with estrogen add-back therapy, a larger
study would not seem to be justifiable.
Keywords: Endometriosis, Pelvic pain, Estradiol,
Estrogen, Leuprolide, GnRH agonist.
INTRODUCTION
GnRH agonist therapy has been proven to be beneficial
to women with endometriosis-related chronic pelvic
pain,1,2 probably due to a reduction in endometriosis
when estrogen levels are suppressed.3 Unfortunately,
long-term usage of GnRH agonists is limited due to prob-
lems associated with the hypoestrogenic state, including
hot flushes, headaches, vaginal dryness and osteoporo-
sis.  The level of estrogen that causes progression of
endometriosis is not known.  At a low level, estrogen
may protect against osteoporosis without stimulating the
disease, whereas a higher level may promote progressive
symptoms.4
Combined estrogen and progestin hormone add-back
regimens during GnRH agonist therapy of endometriosis
reduces hypoestrogenic side effects without compromis-
ing efficacy.5-7 In addition, estrogen can be added after
hysterectomy without increasing endometriosis-related
pain.8,9 We hypothesized that low-dose estrogen could
be added to reduce hypoestrogenic side effects during
GnRH agonist therapy without affecting pain relief.  To
test this hypothesis, we initiated a prospective, random-
ized, double-blinded placebo controlled study of delayed
oral estrogen add-back therapy versus placebo during
leuprolide acetate treatment for endometriosis-related
pain.
MATERIALS AND METHODS
Women with persistent or recurrent chronic pelvic pain
after laparoscopic diagnosis and treatment of
endometriosis were eligible for this placebo controlled,
prospective, randomized, double-blinded study.
Thirteen subjects were enrolled after providing institu-
tional review board approved consent.  Demographic
data is shown in Table 1 and indicates a similar makeup
between the two groups.  All were treated with leupro-
lide acetate (TAP Pharmaceuticals, Deerfield, IL) 3.75 mg
intramuscularly for six months.  Subjects were randomly
assigned into treatment or placebo groups by the hospi-
tal’s investigational drug service, and all medications
were prescribed through this department.  Time period
one was considered to be pretherapy visits.  GnRH ago-
nist therapy was initiated on cycle day 1 to 3.  Months 1,
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2 and 3 were considered to be time period two, and all
patients received leuprolide with no supplement.  During
time period three, months 4, 5 and 6 of leuprolide thera-
py, patients received the study medication:  oral estradi-
ol 1 mg daily (Estrace, MeadJohnson Laboratories,
Princeton, NJ) or an identical-appearing placebo to be
taken daily.  All subjects agreed to use barrier contracep-
tion throughout the study.
Daily pain and medication diaries including dysmenor-
rhea, headaches and hot flush scores were kept by the
patient.  Patients were seen for clinic visits prior to initi-
ating therapy, then every four weeks until the completion
of therapy.  Dysmenorrhea, pelvic pain, dyspareunia, hot
flushes and headaches were assessed by verbal question-
ing of the patient at each visit.  Pelvic induration and
pelvic tenderness were scored by physical examination at
each visit and three months following therapy.  Pelvic
tenderness, induration, headaches, and hot flushes were
given a score of 0-3, with 0 = no symptoms, 1 = mild, 2
= moderate, and 3 = severe symptoms.  Pelvic pain, dys-
pareunia and dysmenorrhea were given a score of 0-10
on a linear scale, with 0 indicating no symptoms and 10
representing the most severe symptoms.  Estradiol levels
were obtained at months 4, 5 and 6.
Exclusion criteria for the study included a history of prior
GnRH agonist therapy, history of an emotional disorder,
pregnancy or lactation.  Further exclusions were osteo-
porosis, known or suspected breast cancer, present or
past endometrial hyperplasia or carcinoma, a history of
thrombosis, thrombophlebitis, or thromboembolism and
undiagnosed abnormal genital bleeding.  Usage of oral
contraceptives or other treatment outside the protocol
was not permitted.
The serum estradiol level was measured at visits 4, 5 and
6 by the COAT-A-Count® (Diagnostic Products
Corporation, Los Angeles, CA) alternate “IVF” procedure,
intra-assay CV <5.6%, interassay CV <5.5%.
Statistical Analysis
For the purpose of analysis, the monthly visits were
described as weeks (ie, pre-therapy visit is represented
by week -4, baseline is represented by week 0, and
month 1 of treatment is represented by week 4).  All
analyses were conducted using SAS/STAT Software, ver-
sion 6.11.10 The demographic parameters were com-
pared using an independent samples t-test for each con-
tinuous variable and a Fisher’s exact test for comparisons
of proportions.  Means at each time point for each treat-
ment group were estimated for each dependent variable.
Longitudinal mixed effects analyses were applied to the
four continuous dependent variables of pelvic pain, dys-
menorrhea, dyspareunia, and estradiol.11 According to a
mixed effects model, regression lines were fit through
each of the period two data and the period three data for
the placebo group and the oral estradiol group separate-
ly.  Hypothesis tests were used to determine whether
slopes differed significantly from zero, and contrasts
were used to test whether the period three oral estradiol
slope was significantly different from the period three
placebo group slope.
A generalized estimating equation approach for analyz-
ing repeated ordinal and categorical values was applied
to the four ordinal variables of hot flushes, pelvic ten-
derness, headache and induration.  Because of problems
with available software, this approach was found to be
limited.  Instead, logistic regression analysis with the
assumption of independence was used to analyze the
ordinal variables.12
RESULTS
Seven women were randomized to oral estradiol and six
to placebo.  Demographic data is shown in Table 1 and
indicates a similar makeup between the two groups for
each parameter listed, p>0.05.  Plots of the means and
standard errors for the endometriosis-related symptom
variables of pelvic pain, dysmenorrhea, dyspareunia,
induration and pelvic tenderness were assessed.  A sta-
tistically significant difference was seen between the
period two and period three placebo dysmenorrhea
slopes, as well as between the period two and period
three estrogen therapy dysmenorrhea slopes (Figure 1),
Table 1.  
Demographic Profile
Estrogen Placebo
Age (years) 28.3 (+/- 5.0) 32.4 (+/- 5.2)
Weight (pounds) 156 (+/- 41) 163 (+/- 34)
Height (inches) 64 (+/- 4) 66 (+/- 3)
Smoker 4/7 3/6
Prior pregnancy 7/7 4/6p<0.05.  For the placebo group, the dysmenorrhea scores
decreased at a slower rate during period three than in
period two.  For the oral estradiol group, the dysmenor-
rhea score increased during period two and decreased
during period three.  Additionally, dyspareunia was sig-
nificantly different in the placebo group when the peri-
od two slope was compared to the period three slope
(Figure 2).  
The differences observed between the oral estrogen
study and placebo groups were not statistically signifi-
cant, although the mean pain scores of the oral estrogen
group during period three are usually higher than those
of the placebo group.  This result indicates the oral estra-
diol add-back is likely causing an increase in
endometriosis-related symptoms in the oral estradiol
group.  Because some subjects tended to experience
increased pain, the blind was broken, and the data was
analyzed after these first 13 patients had completed the
study.  Subsequently, the study was terminated and no
further patients were enrolled.  No adjustments were
made to significance levels of hypothesis tests since this
study was stopped due to safety concerns.
The GnRH agonist side effects were evaluated.  As
expected, hot flush and headache mean scores during
time period three are usually lower for the estradiol
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group than for the placebo group, although these differ-
ences were not statistically significant.  This trend toward
fewer hypoestrogenic side effects with estrogen indicates
that the estradiol add-back appears to be effective in
reducing the GnRH agonist related hot flushes.
DISCUSSION
The trend toward increased pain with low-dose estrogen
therapy is surprising.  Estrogen replacement therapy after
menopause reduces menopausal symptoms and lowers
the risk of osteoporosis.13 Estrogen replacement therapy
has been successfully used for patients with endometrio-
sis after hysterectomy and bilateral oophorectomy.5,6
Recurrent endometriosis-related symptoms are uncom-
mon when estrogen replacement therapy is initiated after
surgery.9 Approximately 90% of patients will tolerate
estrogen replacement therapy in this situation without
recurrent pain.14 In this study, we hoped that we could
achieve suppression of endometriosis by three months of
therapy, without recurrence of pain when estrogen was
eventually added back at low levels.
The study was terminated after the first 13 subjects due
to the concerning trend toward recurrent symptoms in
women who received oral estradiol during leuprolide
acetate therapy for endometriosis related pain.  As a
Figure 1. Plots of the means and standard errors for dysmenor-
rhea.  Week -4 indicates the pretreatment visit (time period one).
Week 0 indicates the start of leuprolide therapy (time period
two).  Week 12 is the start of oral estradiol or placebo in addi-
tion to leuprolide (time period three). 
Figure 2. Plots of the means and standard errors for dyspareu-
nia.  Week 4 indicates the pretreatment visit (time period one).
Week 0 indicates the start of leuprolide therapy (time period
two).  Week 12 is the start of oral estradiol or placebo in addi-
tion to leuprolide (time period three).
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result, a statistically significant difference could not be
found between the placebo group and the treatment
group during time period three when pelvic pain, dys-
menorrhea, dyspareunia, induration, hot flushes and
headaches were compared.  Although the progression of
symptoms suggesting deterioration with oral estrogen
cannot be supported by statistical significance, this study
was designed as an exploratory study.
The lack of a statistically significant difference in this
study should be interpreted with caution.  Given the
small sample size, the ability to find significant differ-
ences between the estradiol group and the placebo group
is low.  The power to find a significant difference with
the observed differences between the slopes of the place-
bo group and the estradiol group in this study ranges
from 0.03 for hot flushes to 0.27 for induration.  Since an
acceptable power is generally 0.80, a larger sample size
should demonstrate a difference, if there is one.  Our
intention in this study was to reduce hypoestrogenic
symptoms with estrogen without compromising efficacy
of GnRH agonist therapy.  Clearly, this study did not meet
this goal, since pain tended to increase with estrogen.
However, an expanded study to prove that estrogen treat-
ment is harmful would be unethical.
Delaying the start of estrogen replacement therapy did
not appear to be beneficial in our study.  The delay was
incorporated in the protocol to allow for regression of
endometriosis and pain before adding estrogen.  Effective
relief of endometriosis-related pain occurs by the third
month of GnRH agonist therapy.15 In theory, estrogen
could be added after the maximal benefit had been
achieved in order to minimize the hypoestrogenic side
effects and could be continued for a prolonged interval.
However, delayed add-back of progestin was not found
to be advantageous in one study.16 Based upon the
observations in our study, it is doubtful that the immedi-
ate addition of estrogen would have resulted in a more
acceptable regimen.
Since endometriosis is an estrogen-dependent condition,
physicians have been reluctant to prescribe even low-
dose estrogen for patients during GnRH agonist therapy
for endometriosis.  Recent studies have confirmed the
safety of combined estrogen plus progestin add-back dur-
ing GnRH agonist therapy for endometriosis.  However,
based upon the results of our study, estrogen add-back
therapy without progestin cannot be advised.
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